8 R&D platforms 5 R&D centers located in China & the U.S. 2000+ R&D professionals ~200 Innovative drugs and new formulations • 10+ Production bases for pharmaceutical products • Nano formulation production capacity of 20M doses/year; Biologics fermentation capacity of 250,000L • Chemical drugs production capacity of OSD ~30B tablets/year, production capacity of injection ~3B doses/year • mRNA vaccine commercial production workshop has been built； siRNA commercial production line is under construction Manufa ...

Financial Performance - Group revenue reached RMB 113.1 billion, a YoY increase of 22.3%[11] - Gross profit margin increased to 22.9%, up 2.5 percentage points YoY[11] - Adjusted net profit reached RMB 11.3 billion, a significant YoY increase of 80.9%[11] - Smart EV, AI and other new initiatives revenue reached RMB 29.0 billion, a substantial YoY increase of 199.2%[11] Smartphone and AIoT Business - Global smartphone shipments ranked among the top 3 for 21 consecutive quarters, with a market share of 13.6%[14] - Premium smartphone sales in Chinese Mainland increased to 24.1% of total smartphone units sold, a YoY increase of 4.1 percentage points[14] - IoT and lifestyle products revenue reached RMB 27.6 billion, up 5.6% YoY[85] Smart EV Initiatives - Delivered 108,796 Smart Electric Vehicles, representing a YoY increase of 173.4%[18] - Smart EV sales revenue reached RMB 28.3 billion, up 197.9% YoY[89] User Growth and AI - Global MAU reached 741.7 million[21] - Number of connected devices reached 1,035.5 million[26] R&D Investment - R&D expenses reached RMB 9.1 billion in Q3 2025[31]

Financial Performance - Revenue for Q3 2025 was $2,382 million, up 7.8% QoQ from $2,209 million in 2Q25 and up 9.7% YoY from $2,171 million in 3Q24 [5, 11] - Gross margin was 22.0%, compared to 20.4% in 2Q25 and 20.5% in 3Q24 [6, 12] - Profit from operations was $351 million, compared to $151 million in 2Q25 and $170 million in 3Q24 [7, 13] - Profit attributable to SMIC was $192 million, compared to $132 million in 2Q25 and $149 million in 3Q24 [8, 14] - EBITDA was $1,430 million, compared to $1,129 million in 2Q25 and $1,157 million in 3Q24 [9, 15] Capital Structure and Cash Flow - Total cash on hand was $11,385 million as of September 30, 2025 [18] - Net cash generated from operating activities was $941 million for the three months ended September 30, 2025 [22] Revenue Breakdown - China accounted for 86.2% of total revenue in 3Q25 [26] - 12-inch wafers accounted for 77.0% of wafer revenue in 3Q25 [32] Capacity and Utilization - Monthly capacity reached 1,022,750 (standard logic 8-inch equivalent wafers) in 3Q25 [36] - Utilization rate was 95.8% in 3Q25 [36] Guidance - Revenue for 4Q 2025 is expected to be flat to +2% QoQ [40] - Gross margin for 4Q 2025 is guided to be between 18% and 20% [40]

2025 Third Quarter Results Presentation November 13, 2025 1 Cautionary Note This presentation may contain forward-looking statements relating to the forecasts, targets, outlook, estimates of financial performance, opportunities, challenges, business developments, business plans and growth strategies of Tencent Holdings Limited (the "Company" or "Tencent") and its group companies. These forward-looking statements are based on information currently available to Tencent and are stated here on the basis of the ...

VTech Holdings Limited 2025/2026 Interim Results Announcement Revenue by Region For the six months ended 30 September | (US$ M) | 2025 | % | 2024 | Change | | --- | --- | --- | --- | --- | | North America | 398.3 | 40.2 | 453.1 | -12.1% | | Europe | 429.0 | 43.3 | 462.1 | -7.2% | | Asia Pacific | 150.4 | 15.2 | 159.4 | -5.6% | | Other Regions | 13.4 | 1.3 | 15.1 | -11.3% | | Total | 991.1 | 100.0 | 1,089.7 | -9.0% | 13 November 2025 Financial Review 2 Financial Highlights For the six months ended 30 Septemb ...

Financial Performance - Net sales decreased by 1.3% in Q3 2025, but showed sequential improvement compared to a 5.8% decrease in Q2 2025[14] - DTC net sales increased by 3.5% in Q3 2025, with DTC e-commerce up 10.1%[14] - Q3 2025 gross margin remained strong at 59.6%, a 30 basis point improvement period-over-period[14] - Adjusted EBITDA decreased by US$12 million from Q3 2024[58] - Adjusted net income decreased by US$16 million mainly due to lower adjusted EBITDA and higher depreciation[56] Regional Performance - North America net sales decreased by 4.5% in Q3 2025, but improved sequentially from a decrease of 7.3% in Q2 2025[63] - Asia net sales were approximately flat, down 0.3% in Q3 2025, a significant improvement compared to a 7.6% decrease in Q2 2025[63] - Europe net sales were up 0.9% in Q3 2025 compared to down 0.9% in Q2 2025[66] - Latin America net sales growth improved to +1.2% in Q3 2025 compared to down 2.2% in Q2 2025[66] Brand Performance - Samsonite brand net sales growth sequentially improved to -4.1% in Q3 2025 from -4.9% in Q2 2025[19] - TUMI brand net sales growth sequentially improved to 5.0% in Q3 2025 from -3.0% in Q2 2025[19] - American Tourister brand net sales growth sequentially improved to -3.7% in Q3 2025 from -14.4% in Q2 2025[19]

Financial Performance - Sales decreased slightly by 1% from US$1,854.2 million to US$1,833.5 million[76, 83] - Gross profit increased slightly from US$438.1 million to US$440.7 million, with gross margin improving by 0.4% to 24.0%[76] - Adjusted net profit decreased from US$133.3 million to US$123.0 million, primarily due to price adjustments and wage inflation[76, 101] - Capital expenditure increased significantly by US$33.2 million, reaching US$130.8 million, representing 7.1% of sales[76] - Free cash flow from operations increased by US$30.1 million, reaching US$174.5 million[76] Business Segments and Markets - Automotive Products Group (APG) sales softened due to unfavorable customer mix in China and competitive price adjustments[83] - Industry Products Group (IPG) sales were flat amid varied regional dynamics, with Asia-Pacific declining due to price competition[83, 97] - The company is well-positioned for growth in New Energy Vehicles (NEV), targeting hybrid and BEV applications[7, 46] Strategic Initiatives - The company is expanding into the humanoid robotics sector through joint ventures in China with SMEIC[127, 131] - Focus on technological innovation to provide unique motion solutions and redefine industry standards[15] - The company is focusing on sustainable growth prospects, supported by megatrends[58]

Group Overview - 9M25 total revenue was US$6,017.4 million[11], with athletic/outdoor shoes accounting for 55% and Pou Sheng contributing 29.7%[10] - 2024 revenue reached US$8,182 million, profit attributable to owners was US$393 million, and dividend per share was HK$1.30[13] - Shoe volume increased by 17% to 255 million pairs in 2024, while ASP decreased by 5.1% to US$20.25[13] - The company is committed to reducing emissions by 46.2% by 2030 compared to 2019[23] Financial Performance (9M25 vs 9M24) - Group revenue decreased by 1% to US$6,017.4 million[42, 53] - Manufacturing revenue increased by 2.3% to US$4,231.7 million[42, 65] - Retail revenue (Pou Sheng) decreased by 7.7% to RMB 12,903 million[42] - Profit attributable to owners decreased by 16% to US$278.7 million[42, 53] - Manufacturing profit attributable to owners decreased by 12.6% to US$263.9 million[42, 65] - Retail profit attributable to owners decreased by 50.1% to RMB 171 million[42] Manufacturing Business - Shoe volume increased by 1.3% YoY to 189.4 million pairs[40, 49] - ASP increased by 3.2% YoY to US$20.88 per pair[40] - Manufacturing gross profit margin was 18.3%, a decrease of 1.3 percentage points[40, 65] - Manufacturing operating profit margin was 6.6%, a decrease of 1.3 percentage points[40, 65] Retail Business (Pou Sheng) - Online contribution reached a historical high, accounting for 33% of total sales[98] - Number of direct operated stores decreased by 3.5% YoY[109]

GenScript Biotech Corporation Overview - GenScript Biotech Corporation aims to be a leading global CDMO, known for cutting-edge technology, and a creator of solutions for a better life through bio-innovation[6] - The company's growth framework is built on innovation in DNA synthesis & design, protein design & engineering, and cell design & engineering[7] - The group's cash position is $966.6 million[11] - GenScript has a global presence, serving over 100 countries and regions with 200,000+ customers[14] Business Strategy and Financial Goals - By 2035, GenScript aims for $3 billion in revenue with over 20% operating margin, $3 billion accumulated licensing revenue, 50% revenue from products, and over 80% revenue from high-margin markets[20, 46] - The company is focusing on high-quality growth with better profitability[20] - GenScript is leveraging core technology advantages to accelerate products and high-value licensing, building a new growth engine with AI and digital engine[20] GenScript Life Science Group (LSG) - GenScript LSG has over 239,500 customers and 3,300+ employees, with 10% in R&D[59] - Accumulated citations of GenScript services & products in customer research publications exceed 112,200[65] - TurboCHOTM can produce antibodies from sequence in 5 days[98] ProBio (Biologics CRDMO) - ProBio aims to be a leading global CDMO, enabling customers to deliver life-changing therapies[6, 127] - The company has $371.1 million in cash position[137] - The biologics CDMO market is projected to be a $16 billion market with a 12% CAGR, while the CGT CDMO market is at $5.6 billion[166] - In vivo CAR-T trial starts grew 220% from 2024 to 2025[166] Bestzyme (Industrial Synthetic Biology) - Bestzyme's vision is to be the creator of solutions for a better life, powered by leading bio-innovation[6, 224] - The company has over 40% of staff in R&D, 60+ granted patents, and 130+ patent applications[233] - Bestzyme has a 23% revenue CAGR and 22% gross profit CAGR in 2022-2024[233]

12 Nov 2025 Pou Sheng International 2025 9M Results Disclaimer Yue Yuen and Pou Sheng have taken every reasonable care in preparing this presentation. However, please be reminded that the information, materials, opinions and statements contained or referred to in this presentation are all provided on an "as is" basis. None of the aforesaid information, materials, opinions and statements constitutes or will be viewed as investment advice or an offer, or a solicitation, recommendation or suggestion by Yue Yue ...